We are pleased to announce that we have successfully completed the FDA Establishment Registration & Device Listing, enhancing our commitment with the U.S. market. This milestone comes after receiving our FDA 510(k) clearance in 2021, which validated the safety and effectiveness of our MAPP® Solution.
To ensure compliance and ongoing communications with the FDA, we have appointed an U.S. Agent, qualifying us to leverage our solutions into the U.S. Market.
We have started the implementation of MAPP® solutions at the Local Health Unit in Amadora / Sintra BIQ HS is the partner chosen to support ULSASi in this project, which […]
+